These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). Rubie H; Michon J; Plantaz D; Peyroulet MC; Coze C; Frappaz D; Chastagner P; Baranzelli MC; Méchinaud F; Boutard P; Lutz P; Perel Y; Leverger G; de Lumley L; Millot F; Stéphan JL; Margueritte G; Hartmann O Br J Cancer; 1998 Jun; 77(12):2310-7. PubMed ID: 9649151 [TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531. Barr EK; Naranjo A; Twist CJ; Tenney SC; Schmidt ML; London WB; Gastier-Foster J; Adkins ES; Mattei P; Handler MH; Matthay KK; Park JR; Maris JM; Desai AV; Cohn SL Pediatr Blood Cancer; 2024 Aug; 71(8):e31089. PubMed ID: 38822537 [TBL] [Abstract][Full Text] [Related]
6. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. Twist CJ; Schmidt ML; Naranjo A; London WB; Tenney SC; Marachelian A; Shimada H; Collins MH; Esiashvili N; Adkins ES; Mattei P; Handler M; Katzenstein H; Attiyeh E; Hogarty MD; Gastier-Foster J; Wagner E; Matthay KK; Park JR; Maris JM; Cohn SL J Clin Oncol; 2019 Dec; 37(34):3243-3255. PubMed ID: 31386611 [TBL] [Abstract][Full Text] [Related]
7. Neuroblastoma. Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023 [TBL] [Abstract][Full Text] [Related]
9. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Gigliotti AR; Di Cataldo A; Sorrentino S; Parodi S; Rizzo A; Buffa P; Granata C; Sementa AR; Fagnani AM; Provenzi M; Prete A; D'Ippolito C; Clerico A; Castellano A; Tonini GP; Conte M; Garaventa A; De Bernardi B Eur J Cancer; 2009 Dec; 45(18):3220-7. PubMed ID: 19767197 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642 [TBL] [Abstract][Full Text] [Related]
11. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique. Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O; Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897 [TBL] [Abstract][Full Text] [Related]
12. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. Twist CJ; Naranjo A; Schmidt ML; Tenney SC; Cohn SL; Meany HJ; Mattei P; Adkins ES; Shimada H; London WB; Park JR; Matthay KK; Maris JM J Clin Oncol; 2019 Jan; 37(2):115-124. PubMed ID: 30444686 [TBL] [Abstract][Full Text] [Related]
13. [Evaluation of efficacy of treatment for 30 children with neuroblastoma]. Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065 [TBL] [Abstract][Full Text] [Related]
14. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study. Kohler JA; Rubie H; Castel V; Beiske K; Holmes K; Gambini C; Casale F; Munzer C; Erminio G; Parodi S; Navarro S; Marquez C; Peuchmaur M; Cullinane C; Brock P; Valteau-Couanet D; Garaventa A; Haupt R Eur J Cancer; 2013 Nov; 49(17):3671-9. PubMed ID: 23907002 [TBL] [Abstract][Full Text] [Related]
15. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689 [TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma: outcome over a 14 year period from a tertiary care referral centre in India. Agarwala S; Mandelia A; Bakhshi S; Srinivas M; Bajpai M; Gupta AK; Gupta DK; Bhatnagar V J Pediatr Surg; 2014 Aug; 49(8):1280-5. PubMed ID: 25092090 [TBL] [Abstract][Full Text] [Related]
17. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715 [TBL] [Abstract][Full Text] [Related]
18. Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Castel V; Cañete A; Navarro S; García-Miguel P; Melero C; Acha T; Navajas A; Badal MD Med Pediatr Oncol; 2001 Dec; 37(6):537-42. PubMed ID: 11745893 [TBL] [Abstract][Full Text] [Related]
19. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. Strother DR; London WB; Schmidt ML; Brodeur GM; Shimada H; Thorner P; Collins MH; Tagge E; Adkins S; Reynolds CP; Murray K; Lavey RS; Matthay KK; Castleberry R; Maris JM; Cohn SL J Clin Oncol; 2012 May; 30(15):1842-8. PubMed ID: 22529259 [TBL] [Abstract][Full Text] [Related]
20. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]